Brief: I-Mab Provides Business And Corporate Updates And Reports Financial Results For The Year Ended December 31, 2022

NovaBridge Biosciences

31/03/2023 11:51

March 31 (Reuters) - I-Mab  IMAB.O :
    * I-MAB PROVIDES BUSINESS AND CORPORATE UPDATES AND REPORTS
FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022
    * I-MAB - CASH POSITION OF RMB3.5 BILLION (US$514.2 MILLION)
BY
END OF 2022, SUFFICIENT TO FUND KEY BUSINESS OPERATIONS FOR NEXT
THREE YEARS
    * I-MAB - AS OF DEC 31, 2022, HAD CASH, CASH EQUIVALENTS,
RESTRICTED CASH, AND SHORT-TERM INVESTMENTS OF RMB3.5 BILLION
(US$514.2 MILLION)
    * I-MAB - 2022 NET LOSS PER SHARE RMB12.71 (US$1.84)
    * I-MAB - 2022 NET LOSS PER ADS RMB29.23 (US$4.24)

Source text for Eikon:  ID:nPnbwPhT2a 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))